Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years

Blood

Volumn 102, Issue 8, 2003, Pages 3052-3059

  Wong, Raymond ^b   Giralt, Sergio A ^b   Martin, Thomas ^b   Couriel, Daniel R ^b   Anagnostopoulos, Athanasios ^b   Hosing, Chitra ^b   Andersson, Borje S ^b   Cano, Pedro ^b   Shahjahan, Munir ^b   Ippoliti, Cindy ^b   Estey, Elihu H ^b   McMannis, John ^b   Gajewski, James L ^b   Champlin, Richard E ^b   De Lima, Marcos ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYTARABINE; FLUDARABINE; GANCICLOVIR; IMATINIB; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; AGED; ARTICLE; CANCER MORTALITY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; FUNCTIONAL ASSESSMENT OF CANCER THERAPY BONE MARROW TRANSPLANT SCALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTERVIEW; MALE; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME;

EID: 0141958295     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-03-0855     Document Type: Article

References (36)

1. de Lima M, Champlin R. Unrelated donor hematopoietic transplantation. Rev Clin Exp Hematol. 2001;5:100-134.
2. Ries LA, Kosary CL, Hankey BF, et al, eds. SEER Cancer Statistics Review, 1973-1996. Bethesda, MD: National Cancer Institute; 1999.
3. Latagliata R, Petti M, Mandelli F. Acute myelogenous leukemia in the elderly: "per aspera ad astra?" Leuk Res. 1999;23:603-605.
4. Ringden O, Remberger M, Mattsson J, et al. Transplantation with unrelated bone marrow in leukaemic patients above 40 years of age. Bone Marrow Transplant. 1998;21:43-49.
5. International Bone Marrow Transplant Registry. Allogeneic Transplants for Patients >20 Years by Donor Type, Registered with the IBMTR, 1986-2000. Slide number 10. 2001. Available at: http://instruct.mcw.edu/IBMTR/BwebServer/Summarysldset/summset_files/ v3_document.htm. Accessed December 2002.
6. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 1993;328:593-602.
7. McGlave PB, Shu XO, Wen W, et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood. 2000;95:2219-2225.
8. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89:4531-4536.
9. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
10. Przepiorka D, Ippoliti D, Khouri I, et al. Tacrolimus and minidose methotrexate for prevention of acute graft versus host disease after matched unrelated donor marrow transplantation Blood. 1996;88:4383-4389.
11. Yam PY, Petz LD, Knowlton RG, et al. Use of DNA restriction fragment length polymorphisms to document marrow engraftment and mixed hematopoietic chimerism following bone marrow transplantation. Transplantation. 1987;43:399-407.
12. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988;6:1562-1568.
13. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825-828.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
15. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
16. McQuellon RP, Russell GB, Cella DF, et al. Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale. Bone Marrow Transplant. 1997;19:357-368.
17. de Lima M, Strom SS, Keating M, et al. Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work. Blood. 1997;90:4719-4724.
18. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
19. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390-3400.
20. Giralt S, Thai PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97:631-637.
21. Gale R, Bortin M, van Bekkum D, et al. Risk factors for acute graft versus host disease. Br J Haematol. 1987;67:397-406.
22. Ferrara J, Deeg H. Graft versus host disease. N Engl J Med. 1991;324:667-674.
23. Ordemann R, Hutchinson R, Friedman J, et al. Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft-versus-host disease. J Clin Invest. 2002;109:1249-1256.
24. Poulin J, Viswanathan M, Harris J, et al. Direct evidence for thymic function in adult humans. J Exp Med. 1999;190:479-486.
25. Ringden O, Horowitz M, Gale R, et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA. 1993;270:57-60.
26. Dini G, Cancedda R, Locatelli F, et al. Unrelated donor marrow transplantation: an update of the experience of the Italian Bone Marrow Group (GITMO). Haematologica. 2001;86:451-456.
27. National Marrow Donor Program. NMDP Transplant Outcomes for Chronic Myelogenous Leukemia. 2001. Available at: http://www.marrow.org/MEDICAL/disease_outcome_data.html. Accessed December 2002.
28. Hansen JA, Mickelson E, Petersdorf EW, et al. Marrow transplants from unrelated donors. Clin Transpl. 1995;9:279-289.
29. Sierra J, Storer B, Hansen JA, et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant. 2000;26:397-404.
30. Castro-Malaspina H, Harris RE, Gajewski J, et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. blood. 2002;99:1943-1951.
31. Davies SM, Kollman C, Anasetti C, et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. Blood. 2000;96:4096-4102.
32. Kopp M, Schweigkofler H, Holzner B, et al. Time after bone marrow transplantation as an important variable for quality of life: results of a cross-sectional investigation using two different instruments for quality-of-life assessment. Ann Hematol. 1998;77:27-32.
33. Heinonen H, Volin L, Uutela A, et al. Quality of life and factors related to perceived satisfaction with quality of life after allogeneic bone marrow transplantation. Ann Hematol. 2001;80:137-143.
34. Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98:2942-2947.
35. Petersdorf E, Gooley T, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood. 1998;92:3515-3520.
36. Sierra J, Storer B, Hansen JA, et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood. 1997;89:4226-4235.